iiinova — where your digital self keeps evolving

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 24/09/2026

Our new review is published in Neuroscience & Biobehavioral Reviews! We analyzed global data on 35 neurological, mental, and substance use disorders. Together, these conditions account for 10 of the 25 leading causes of disability worldwide. doi.org/10.1016/j.ne...

010

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 19/05/2026

New publication! 🧠 Excited to share our latest paper, for which I am co-first author. This randomized controlled trial provides the first evidence that #buprenorphine can prolong and augment #ketamine’s antisuicidal effects in #depression. doi.org/10.1176/appi...

230

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/05/2026

I’m very happy to share our new paper, recently published in iScience. Paper: doi.org/10.1016/j.is...

110

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 20/02/2026

Loved attending the Brazil Global Health Initiative event yesterday at Stanford. Always inspiring to connect with brilliant Brazilian researchers doing amazing work across Silicon Valley. Proud to be part of this community! 🇧🇷

020

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 21/01/2026

What an experience at #ACNP2026! Honored to present our Stanford randomized clinical trial demonstrating a novel strategy to sustain the antisuicidal effects of #ketamine in #depression as part of our mini-panel on buprenorphine and suicidality. @acnporg.bsky.social

131

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/01/2026

Grateful to be back at #ACNP2026, supported by my Past Travel Awardee Funding! I'm a Stanford postdoc leading trials in interventional psychiatry with #BrainStimulation and #Ketamine for depression and suicide prevention. Join our mini-panel on 01/13 and poster on 01/15! @acnporg.bsky.social

021

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 14/11/2025

Check out our new commentary in the International Journal of Neuropsychopharmacology (@ijnp.bsky.social) on ketamine–naltrexone clinical trial design for depression. doi.org/10.1093/ijnp...

030

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 20/08/2025

Privileged our mini-panel was selected for #ACNP2026 @acnporg.bsky.social. Grateful to join Drs. J. John Mann (‪Columbia‬), Alan Schatzberg (Stanford), Mina Rizk (Mount Sinai) and Yunyu Xiao (Cornell). Looking forward to the discussions ahead!

050

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/08/2025

Proud to receive the American College of Neuropsychopharmacology (ACNP) Past Travel Awardee Funding, recognizing my ongoing research progress. #ACNP2025 @acnporg.bsky.social

020

Reposted by Igor D. Bandeira, MD, PhD

NIHR Biomedical Research Centre: Maudsley @nihrmaudsleybrc.bsky.social · 24/07/2025

Research which is investigating why ketamine could be a good treatment for some people with depression, has discovered that the drug’s antidepressant effects involve the brain’s opioid system. The study was supported by @nihr.bsky.social and the MRC. www.maudsleybrc.nihr.ac.uk/posts/2025/j...

Dr Luke Jelen, lead author of the study and a Clinical Lecturer in Psychiatry at IoPPN King’s College London, said:

“Ketamine often makes the news for negative reasons. However, at a low dose, ketamine shows enormous potential to offer relief from the symptoms of depression.”

“Understanding whether the opioid system is involved ketamine’s antidepressant effects is a really important question, given how much we still don't know about how ketamine works. “Our study shows that the opioid system is involved and offers insight into how it contributes to ketamine’s effects.”

022

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 09/06/2025

Spoke with @peerj.bsky.social‬ about my research after receiving 1st Prize for Best Poster at the Winter Conference on Brain Research 2025. #WCBR2025 peerj.com/blog/post/11... Grateful for the chance to share what drives my work in interventional psychiatry.

141

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 22/05/2025

Thrilled to share that our book chapter has just been published as part of #Bipolar Disorder: An Evidence-Based Clinical Guide (Springer Nature, 2025).

230

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 07/05/2025

I’m deeply grateful to the Anxiety and Depression Association of America (@adaaanxiety.bsky.social) for honoring me with the Alies Muskin Career Development Leadership Award this year. #ADAA2025

120

Reposted by Igor D. Bandeira, MD, PhD

Suicide Research Symposium @suicideresearchsym.bsky.social · 21/04/2025

The fourth annual Suicide Research Symposium (#SRS25) takes place THIS WEEK, Wednesday (April 23) through Friday (April 25)! Registration is still open for our free, virtual event. Links to register and see the conference platform are on our website: www.suicideresearchsymposium.com

suicideresearchsymposium.com

SRS 2025

We are delighted to announce that the fourth annual Suicide Research Symposium will be taking place April 23-25, 2025. Like previous years, this Symposium will be free and take place virtually. We ...

12317

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 20/03/2025

Happy to share that I have been selected for the Alies Muskin Career Development Leadership Award from the Anxiety and Depression Association of America (@adaaanxiety.bsky.social)! #ADAA2025

130

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 06/03/2025

It was a great honor to receive the New Investigator Award and share the preliminary data from our @afspnational.bsky.social study at the 21st Annual Meeting of the International Society for CNS Clinical Trials and Methodology in Washington, DC. #ISCTM2025

110

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 18/02/2025

Honored to have been selected for the New Investigator Award from the International Society for CNS Clinical Trials and Methodology! This recognition aligns with my passion for advancing rigorous and innovative research methodologies to improve psychiatric care. #ISCTM #ISCTM2025

110

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 10/02/2025

First prize for Best Poster Presentation at the Winter Conference on Brain Research 2025! This recognition is a reminder that perseverance pays off, even in challenging times. Proud and grateful! #WCBR #WCBR2025

010

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 09/02/2025

I’m Still Here is a raw and unconventional exploration of identity, struggle, and reinvention. It reminds us that pain and adversity, rather than breaking us, can serve as catalysts for transformation.

130

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 04/02/2025

Attending the Winter Conference on Brain Research as a Travel Fellowship Awardee was an incredible opportunity to exchange ideas with peers across preclinical and clinical research. #WCBR #WCBR2025

140

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 27/01/2025

Happy to be in beautiful Tahoe as a Travel Fellowship Awardee at the Winter Conference on Brain Research! If you're curious about interventional psychiatry, the opioid properties of #ketamine, and treatment-resistant #depression, stop by my poster tomorrow (Board #31)! #WinterBrain #WCBR2025

060

Reposted by Igor D. Bandeira, MD, PhD

Roxana Daneshjou, MD, PhD @roxanadaneshjou.bsky.social · 25/01/2025

The NIH diversity supplement pages have all been pulled down. What is a diversity supplement and why should the public care? A diversity supplement is funding to help diversify the research workforce. You may be wondering, “so what?”. Let me explain. www.nigms.nih.gov/Pages/PageNo...

nigms.nih.gov

National Institute of General Medical Sciences

NIGMS supports basic research to understand biological processes and lay the foundation for advances in disease diagnosis, treatment, and prevention.

9494277

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 14/12/2024

Feeling deeply grateful after an incredible #ACNP2024! It was an honor to connect with inspiring colleagues, foster new connections, and reunite with lifelong friends. Special thanks to the #TravelAward2024 program for the invaluable mentorship and support. @acnporg.bsky.social

2133

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 11/12/2024

Our poster T16 on #ketamine for suicidal behavior in treatment-resistant #depression is up now at #ACNP2024! Let's discuss the comparative analysis of antisuicidal and antidepressant effects!

031

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 10/12/2024

Attending the recent panel on #suicideprevention at #ACNP2024 was truly thought-provoking. The dedication, innovative research, and shared commitment underscore the urgent need to advance effective interventions for this critical public health issue. @acnporg.bsky.social

081

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 08/12/2024

Hey #ACNP2024! Grateful to return for my 2nd year, this time as a Travel Awardee! I’m a postdoc at Stanford, working on interventional psychiatry clinical trials with #BrainStimulation and #Ketamine for depression. Hope to see you at my poster (T16) on 12/10!

1161

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 05/12/2024

Honored to be part of this incredible group of travel awardees. #ACNP2024 #TravelAward2024

181

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 28/11/2024

I am thrilled to announce that I have been honored with a Travel Fellowship Award to attend the 2025 Winter Conference on Brain Research!

140

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 18/11/2024

Recruitment is ongoing for our study titled "Opiate Suicide Study in Patients with Major Depression" at Stanford University, sponsored by the American Foundation for Suicide Prevention.

163

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 30/10/2024

Excited to share that our paper, demonstrating how early changes in lassitude can predict response to Stanford Neuromodulation Therapy in treatment-resistant depression, has been published in npj Mental Health Research, part of the @natureportfolio.bsky.social. www.nature.com/articles/s44...

0103

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 26/07/2024

Beyond happy to share that I am one of the recipients of the American College of Neuropsychopharmacology 2024 Travel Awards! Grateful to my mentors and colleagues who inspired me on this journey and provided valuable feedback on my application. #ACNP2024

050

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/07/2024

Honored to announce that I've joined the editorial board of Springer Nature's BMC Psychiatry! Proud to support the dissemination of impactful research in mental health. bmcpsychiatry.biomedcentral.com/about/editor...

010

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 05/06/2024

Thrilled to attend the #ASCP2024 this past week as a New Investigator Awardee! The experience was invaluable, from building a network of mentors beyond my Stanford community to receiving helpful feedback on our preliminary data presentation.

010

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 28/05/2024

Excited to be at my first American Society of Clinical #Psychopharmacology Annual Meeting and deeply honored to receive the New Investigator Award (NIA)! Connecting with peers and mentors at the NIA Workshop was incredibly inspiring. Looking forward to the upcoming activities and panels! #ASCP2024

010

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 24/05/2024

Sharing the good news that a #ketamine paper I co-authored with the Neuropsychopharmacology Lab (UFBA) in Brazil has been recognized as one of the top 10 most-cited and downloaded in the journal Human Psychopharmacology! #TopCitedArticle #TopDownloadedArticle Link: doi.org/10.1002/hup....

011

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 23/05/2024

Yesterday, I attended my first #nerdniteSF and was captivated by @nkwhiteman.bsky.social’s talk on his new book, Most Delicious Poison, which explores nature’s toxins and why we are attracted—and addicted—to them. Can’t wait to read it!

020

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 15/05/2024

I had such an incredible experience at #SOBP2024! 🧠 More than just a conference, it was a chance to reconnect with old friends and make new connections. Grateful for the opportunity to immerse myself in cutting-edge research and vibrant discussions! #Ketamine #Depression #SuicidePrevention

010

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 09/05/2024

Hey #SOBP2024 community! As a Stanford Postdoc, I've worked on #brainstimulation and #ketamine clinical trials for treatment-resistant #depression. Look out for my poster presentation (F151) tomorrow. I'm eager to connect with fellow researchers and share our data.

010

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 08/05/2024

Feeling privileged to have been a travel awardee at the American Society of Hispanic #Psychiatry Annual Meeting in NYC! Sharing preliminary results from our AFSP funded trial on #ketamine / buprenorphine for suicide behavior and fostering invaluable connections was truly amazing. #APAAM24

010

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 12/10/2023

19th Annual Mood Disorders Education Day Saturday, October 14, 2023 9:00 AM – 1:00 PM (PT) Translating Emerging Treatments for Mood Disorders Into Practice t.co/QwGV32vAgH

t.co

19th Annual Mood Disorders Education Day

19th Annual Mood Disorders Education Day will be a Webinar on Translating Emerging Treatments for Mood Disorders Into Practice

000

Igor D. Bandeira, MD, PhD @igorbandeira.bsky.social · 06/07/2023

Proud to share my latest first authorship! This is the first clinical trial testing IV arketamine for bipolar depression. Subjects received two infusions one week apart—0.5 mg/kg first and then 1 mg/kg, showing rapid-acting antidepressant properties. doi.org/10.1016/j.jpsychires.2023.0…

150